| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 70518-4243-00 | 70518-4243 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 20, 2024 | In Use | |
| 50242-0210-60 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jul 1, 2021 | Sep 30, 2026 | In Use |
| 50090-2098-00 | 50090-2098 | Methylprednisolone Acetate | Depo-Medrol | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intralesional, Intramuscular, Soft Tissue | Oct 13, 2015 | In Use | |
| 10019-0955-01 | 10019-0955 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 21, 2008 | In Use | |
| 00781-3258-70 | 00781-3258 | bortezomib for injection | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | May 31, 2022 | In Use | |
| 50242-0210-83 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jul 1, 2021 | Sep 30, 2026 | In Use |
| 00832-0532-09 | 00832-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 17, 2024 | In Use | |
| 69539-0159-01 | 69539-0159 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 26, 2020 | In Use | |
| 54868-3826-07 | 54868-3826 | Methotrexate sodium | Methotrexate Sodium | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec 5, 2007 | In Use | |
| 50242-0090-01 | 50242-0090 | Vemurafenib | Zelboraf | 240.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Aug 17, 2011 | Feb 28, 2018 | In Use |
| 00378-0344-01 | 00378-0344 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 63304-0094-27 | 63304-0094 | Sunitinib malate | Sunitinib malate | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 25, 2019 | In Use | |
| 10631-0118-31 | 10631-0118 | Isotretinoin | Absorica | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jun 8, 2012 | In Use | |
| 87063-0042-30 | 87063-0042 | PREDNISONE | PREDNISONE | 2.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 3, 2025 | In Use | |
| 47335-0472-13 | 47335-0472 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
| 00095-0087-35 | 00095-0087 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 1, 2006 | In Use | |
| 63539-0189-11 | 63539-0189 | Palbociclib | Ibrance | 125.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Feb 3, 2015 | In Use | |
| 50242-0210-86 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sep 15, 2020 | Feb 11, 2022 | In Use |
| 60760-0637-15 | 60760-0637 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 3, 2020 | In Use | |
| 68788-6774-09 | 68788-6774 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct 24, 2016 | In Use | ||
| 50242-0201-01 | 50242-0201 | Mosunetuzumab | Lunsumio Velo | 45.0 mg/mL | Immunotherapy | Bispecific Antibody | CD20, CD3 | Subcutaneous | Dec 19, 2025 | In Use | |
| 50242-0210-90 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jul 1, 2021 | Sep 30, 2026 | In Use |
| 54868-0235-00 | 54868-0235 | Triamcinolone Acetonide | Kenalog-40 | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | Jun 11, 1996 | In Use | |
| 51655-0016-53 | 51655-0016 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 16, 2022 | In Use | |
| 51655-0933-87 | 51655-0933 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 20, 2022 | In Use |
Found 12159 results — Export these results
Home